These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention. Joy S, Rhea DJ, Istwan NB, Desch CN, Stanziano G. Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580 [Abstract] [Full Text] [Related]
11. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, Schwarz RH, Damus K. Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150 [Abstract] [Full Text] [Related]
12. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting. Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R. Am J Obstet Gynecol; 2007 Sep; 197(3):262.e1-4. PubMed ID: 17826412 [Abstract] [Full Text] [Related]
15. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Rozenberg P, Chauveaud A, Deruelle P, Capelle M, Winer N, Desbrière R, Perrotin F, Bohec C, Connan L, Vayssière C, Langer B, Mantel A, Azimi S, Porcher R, Azria E, Groupe De Recherche En Obstétrique et Gynécologie. Am J Obstet Gynecol; 2012 Mar; 206(3):206.e1-9. PubMed ID: 22381603 [Abstract] [Full Text] [Related]
19. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy. Coleman S, Wallace L, Alexander J, Istwan N. J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134 [Abstract] [Full Text] [Related]